Crenolanib

Crenolanib
Item number Size Datasheet Manual SDS Delivery time Quantity Price
TGM-T2677-2mg 2 mg

7 - 10 business days*

54.00€
TGM-T2677-5mg 5 mg

7 - 10 business days*

81.00€
TGM-T2677-1mL 1 ml

7 - 10 business days*

91.00€
TGM-T2677-10mg 10 mg

7 - 10 business days*

131.00€
TGM-T2677-25mg 25 mg

7 - 10 business days*

195.00€
TGM-T2677-50mg 50 mg

7 - 10 business days*

281.00€
TGM-T2677-100mg 100 mg

7 - 10 business days*

466.00€
 
Description: Crenolanib (ARO 002) is an orally bioavailable type III tyrosine kinases inhibitor... more
Product information "Crenolanib"
Description: Crenolanib (ARO 002) is an orally bioavailable type III tyrosine kinases inhibitor of PDGFRalpha/beta and FLT3 (IC50s: 11, 3.2, and 4 nM). Target: Autophagy, FLT, PDGFR. Smiles: CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1. References: Heinrich MC, et al.Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res, 2012, Jun 27.
Keywords: CP-868596, ARO 002
Supplier: TargetMol
Supplier-Nr: T2677

Properties

Application: Targets fms-related tyrosine kinase 3 [EC:2.7.10.1] (FLT3, FLK2, CD135)
MW: 443.54 D
Formula: C26H29N5O2
Format: 32160405

Database Information

CAS : 670220-88-9| Matching products
KEGG ID : K05092 | Matching products

Handling & Safety

Storage: -20°C
Shipping: +4°C (International: +4°C)
Caution
Our products are for laboratory research use only: Not for administration to humans!
Information about the product reference will follow. more
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "Crenolanib"
Write a review
or to review a product.
Viewed